相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial
Maartje E. Visser et al.
EUROPEAN HEART JOURNAL (2012)
Effect of Lipid-Lowering Treatment on Natural History of Heterozygous Familial Hypercholesterolemia in Past Three Decades
Avishay Elis et al.
AMERICAN JOURNAL OF CARDIOLOGY (2011)
Lipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hypercholesterolemia
Marit S. Nenseter et al.
ATHEROSCLEROSIS (2011)
ESC/EAS Guidelines for the management of dyslipidaemias (vol 32, pg 1769, 2011)
Alberico L. Catapano et al.
ATHEROSCLEROSIS (2011)
MIPOMERSEN, AN APOB SYNTHESIS INHIBITOR, EVALUATION OF POTENTIAL TO REDUCE NECESSITY FOR LIPID-APHERESIS IN PATIENTS WITH HETEROZYGOUS FH AND CAD
K. G. Parhofer et al.
ATHEROSCLEROSIS SUPPLEMENTS (2011)
Mipomersen, an antisense apolipoprotein B synthesis inhibitor
Damon A. Bell et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice
Adam E. Mullick et al.
JOURNAL OF LIPID RESEARCH (2011)
Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study
Stefania Lamon-Fava et al.
JOURNAL OF LIPID RESEARCH (2011)
Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia
Fatima Akdim et al.
AMERICAN JOURNAL OF CARDIOLOGY (2010)
Comparison of Atorvastatin 80 mg/day Versus Simvastatin 20 to 40 mg/day on Frequency of Cardiovascular Events Late (Five Years) After Acute Myocardial Infarction (from the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trial)
Terje R. Pedersen et al.
AMERICAN JOURNAL OF CARDIOLOGY (2010)
RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
C. Frank Bennett et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2010)
Efficacy criteria and cholesterol targets for LDL apheresis
Gilbert R. Thompson et al.
ATHEROSCLEROSIS (2010)
Lipoprotein(a) as a cardiovascular risk factor: current status
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2010)
NLA Symposium screening and treatment of familial hypercholesterolemia: How can we do better? Opening and introductions
Mary McGowan
JOURNAL OF CLINICAL LIPIDOLOGY (2010)
Novel therapies and new targets of treatment for familial hypercholesterolemia
Anne Carol Goldberg
JOURNAL OF CLINICAL LIPIDOLOGY (2010)
A systematic review and meta-analysis on the therapeutic equivalence of statins
T. -C. Weng et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2010)
Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia
Maartje E. Visser et al.
JOURNAL OF LIPID RESEARCH (2010)
Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy
Fatima Akdim et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2010)
Two Years after Molecular Diagnosis of Familial Hypercholesterolemia: Majority on Cholesterol-Lowering Treatment but a Minority Reaches Treatment Goal
Roeland Huijgen et al.
PLOS ONE (2010)
The LDL Receptor
Joseph L. Goldstein et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Designing a study to evaluate the effect of apheresis in patients with elevated lipoprotein(a)
U. Kassner et al.
ATHEROSCLEROSIS SUPPLEMENTS (2009)
Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100
Rosie Z. Yu et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2 '-O-Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe
Rosie Z. Yu et al.
CLINICAL PHARMACOKINETICS (2009)
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Robert Clarke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study
Jorie Versmissen et al.
BMJ-BRITISH MEDICAL JOURNAL (2008)
The safety of statins in clinical practice
Jane Armitage
LANCET (2007)
Subendothelial lipoprotein retention as the initiating process in atherosclerosis -: Update and therapeutic implications
Ira Tabas et al.
CIRCULATION (2007)
Antisense apolipoprotein B therapy: where do we stand?
Fatima Akdim et al.
CURRENT OPINION IN LIPIDOLOGY (2007)
Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100
Rosie Z. Yu et al.
DRUG METABOLISM AND DISPOSITION (2007)
Apheresis in coronary heart disease with elevated Lp (a): A review of Lp (a) as a risk factor and its management
Christiane Keller
THERAPEUTIC APHERESIS AND DIALYSIS (2007)
Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia
Marina Cuchel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B
John J. P. Kastelein et al.
CIRCULATION (2006)
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis - The ASTEROID trial
SE Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
High-dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction - The IDEAL study: A randomized controlled trial
TR Pedersen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia
DT Holmes et al.
CLINICAL CHEMISTRY (2005)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
Antisense oligonucleotides as therapeutics for hyperlipidaemias
RM Crooke
EXPERT OPINION ON BIOLOGICAL THERAPY (2005)
An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis
RM Crooke et al.
JOURNAL OF LIPID RESEARCH (2005)
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis - A randomized controlled trial
SE Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Effect of statin treatment for familial hypercholesterolaemia on life assurance: results of consecutive surveys in 1990 and 2002
HAW Neil et al.
BRITISH MEDICAL JOURNAL (2004)
Genetic causes of monogenic heterozygous familial hypercholesterolemia: A HuGE prevalence review
MA Austin et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2004)
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
SM Grundy et al.
CIRCULATION (2004)
The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients
ACM Jansen et al.
JOURNAL OF INTERNAL MEDICINE (2004)
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
J Soutschek et al.
NATURE (2004)
Progress in antisense technology
ST Crooke
ANNUAL REVIEW OF MEDICINE (2004)
Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia
MAW Umans-Eckenhausen et al.
ARCHIVES OF INTERNAL MEDICINE (2003)
The N-terminal 1000 residues of apolipoprotein B associate with microsomal triglyceride transfer protein to create a lipid transfer pocket required for lipoprotein assembly
N Dashti et al.
BIOCHEMISTRY (2002)
Elucidating cell signaling mechanisms using antisense technology
E Koller et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2000)
分享论文
